Ireland
--:--IST
Priya Life Science Medicines register
Registers› Irish medicines ›Vidisic 0.2 % w/w eye gel
Medicines register · Ireland

Vidisic 0.2 % w/w eye gel

Authorisation PA23259/008/001 · Bausch + Lomb Ireland Limited

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 22 Nov 2026
Licence holder
Bausch + Lomb Ireland Limited (all products →)
Active substance
Carbomer
Dosage form
Eye gel
Route of administration
Ocular use
ATC codes
S01XA, S01XA20
First authorised
11/08/1993
Prescription status
Product not subject to medical prescription
Supply
Supply through pharmacies only
Legal basis
Full application (Article 8(3) of Directive No 2001/83/EC)

Carbomer: supply and approvals

5 authorised products on the HPRA list contain Carbomer. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 21 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 21 Nov 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 21 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 33 years (since 11 August 1993). The HPRA list marks it as marketed in Ireland.

Other medicines with Carbomer in Ireland

4 other products on the HPRA list contain Carbomer, from 2 licence holders; 4 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Geltears 0.2 % w/w carbomer eye gelBausch + Lomb Ireland LimitedNational authorisation (PA)Marketed
LIQUIVISC 2.5 mg/g eye gelLaboratoires TheaNational authorisation (PA)Marketed
Liposic 2 mg/g eye gelBausch + Lomb Ireland LimitedNational authorisation (PA)Marketed
Vidisic Preservative Free Single Dose UnitBausch + Lomb Ireland LimitedNational authorisation (PA)Marketed

Other substances in ATC group S01XA

The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 4 other active substances share the group S01XA with this product:

Hypromellose (2) · Carmellose sodium (2) · Ciclosporin (2) · Mercaptamine hydrochloride (1)

Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.

The licence holder

Bausch + Lomb Ireland Limited holds 25 products on the HPRA list, with 19 different active substances; 20 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 22 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.